Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления - Журнал Терапевтический архив №8 Вопросы лечения 2020
Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления
Маев И.В., Шпектор А.В., Васильева Е.Ю. и др. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020; 92 (8): 4–11. DOI: 10.26442/00403660.2020.08.000767
DOI: 10.26442/00403660.2020.08.000767
________________________________________________
DOI: 10.26442/00403660.2020.08.000767
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Новая коронавирусная инфекция COVID-19 в превалирующем большинстве случаев манифестирует респираторными симптомами и лихорадкой, однако у некоторых пациентов могут отмечаться сердечно-сосудистые и гастроэнтерологические проявления. Особенностью клинического синдрома COVID-19 является развитие выраженных иммунопатологических реакций и нарушений гемостаза, ведущее к широкому спектру сердечно-сосудистых осложнений. Течение COVID-19 может осложниться развитием острого инфаркта миокарда, венозных и артериальных тромбозов и тромбоэмболий в различных сосудистых бассейнах, острого повреждения миокарда и миокардита. Среди гастроэнтерологических проявлений наиболее часто выявляются диарея, тошнота или рвота, а также абдоминальная боль. Эти симптомы могут предшествовать появлению респираторных признаков заболевания, а в некоторых случаях выходить на первый план в клинической картине заболевания. Помимо этого, у части больных наблюдаются лабораторные признаки поражения печени (повышение сывороточных трансаминаз). Точный патогенез описанных нарушений продолжает изучаться.
Ключевые слова: COVID-19, SARS-CoV-2, острый инфаркт миокарда, повреждение миокарда, коагулопатия, тромбоз, острый коронарный синдром, диарея, рвота, абдоминальная боль, потеря аппетита.
Key words: COVID-19, SARS-CoV-2, acute myocardial infarction, myocardial damage, coagulopathy, thrombosis, acute coronary syndrome, diarrhea, vomiting, abdominal pain, loss of appetite.
Ключевые слова: COVID-19, SARS-CoV-2, острый инфаркт миокарда, повреждение миокарда, коагулопатия, тромбоз, острый коронарный синдром, диарея, рвота, абдоминальная боль, потеря аппетита.
________________________________________________
Key words: COVID-19, SARS-CoV-2, acute myocardial infarction, myocardial damage, coagulopathy, thrombosis, acute coronary syndrome, diarrhea, vomiting, abdominal pain, loss of appetite.
Список литературы
1. Zhu N, Zhang D, Wang W, et al.; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33. doi: 10.1056/NEJMoa2001017
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-20. doi: 10.1097/JCMA.0000000000000270
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433
4. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
5. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577-82. doi: 10.7326/M20-0504. PMID: 32150748
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. PMID: 32091533.
7. Вступительное слово Генерального директора на пресс-брифинге по COVID-19 11 марта 2020 г. [Opening address by the Director-General at a COVID-19 press briefing on March 11, 2020. Published online at WHO.int. (In Russ.)]. https://www.who.int/ru/dg/speeches/detail/
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
8. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus
9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623
10. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8
11. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017. doi: 10.1001/jamacardio.2020.1017
12. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 17. doi: 10.1016/j.jacc.2020.04.031
13. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;10.1111/jce.14479. doi: 10.1111/jce.14479
14. Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727
15. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb Res. 2020 Apr 10;S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013
16. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;10.1161/CIRCRESAHA.120.317055. doi: 10.1161/CIRCRESAHA.120.317055
17. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation. 2020;10.1161/CIRCULATIONAHA.120.047008. doi: 10.1161/CIRCULATIONAHA.120.047008
18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14850
19. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated With Coronavirus Disease 2019 Infection:
A Consensus Statement Before Guidelines. Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019
20. Tang N, Bai H, Chen X, et al. Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. doi: 10.1111/jth.14817
21. Marone EM, Rinaldi LF. Upsurge of Deep Venous Thrombosis in Patients Affected by COVID-19: Preliminary Data and Possible Explanations. J Vasc Surg Venous Lymphat Disord. 2020 Apr 17;S2213-333X(20)30214-6. doi: 10.1016/j.jvsv.2020.04.004
22. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024
23. Vulliamy P, Jacob S, Davenport RA. Acute Aorto-Iliac and Mesenteric Arterial Thromboses as Presenting Features of COVID-19. Br J Haematol. 2020 Apr 30. doi: 10.1111/bjh.16760
24. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant Acute Aortic Thrombosis and Pulmonary Embolism Complicating COVID-19 Pneumonia. Diagn Interv Imaging. 2020 Apr 16;101(5):321-2. doi: 10.1016/j.diii.2020.04.003
25. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 – A Swiss Consensus Statement by the Working Party Hemostasis. Swiss Med Wkly. 2020 Apr 11;150:w20247. doi: 10.4414/smw.2020.20247
26. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med. 2020 Apr 17: NEJMc2009020. doi: 10.1056/NEJMc2009020
27. Никитская Е.А., Марюхнич Е.В., Саввинова П.П. и др. Вирусы герпеса человека и атеросклероз. Современный взгляд. Креативная кардиология. 2015;9(2):54-62 [Nikitskaya EA, Maryukhnich EV, Savvinova PP, et al. Human herpes viruses and atherosclerosis. Modern look. Creative cardiology. 2015;9(2):54-62 (In Russ.)]. doi: 10.15275/kreatkard.2015.02.05
28. Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae. 2016 Apr-Jun;8(2):102-7.
29. Nikitskaya E, Lebedeva A, Ivanova O, et al. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. J Am Heart Assoc. 2016 Aug 20;5(8):e003759. doi: 10.1161/JAHA.116.003759
30. Воробьева И.И., Рыжкова Е.В., Васильева Е.Ю., Шпектор А.В. Влияние системного воспаления на эффект антиагрегантной терапии у больных с острым коронарным синдромом. Креативная кардиология, 2012;1:5-14 [Vorobyeva II, Ryzhkova EV, Vasilieva EYu, Spector AV. The effect of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome. Creative Cardiology. 2012;1:5-14 (In Russ.)].
31. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;10.1164/rccm.202003-0543OC. doi: 10.1164/rccm.202003-0543OC
32. Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20.
33. Jing ZC, Zhu HD, Yan XW, et al.; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital, Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heat J. doi: 10.1093/eurheartj/ehaa258
34. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020 Apr 23. doi: 10.1016/S0140-6736(20)30912-0
35. Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Complicated With Fulminant Myocarditis: A Case Report and Insights. Infection. 2020 Apr 10. doi: 10.1007/s15010-020-01424-5
36. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Accessed May 10, 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
37. Courand P-Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous Coronary Artery Dissection in a Patient with COVID-19. JACC: Cardiovascular Interventions. 2020. doi: 10.1016/j.jcin.2020.04.006
38. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. doi: 10.1111/jth.14830
39. Thachil J, Tang N, Gando S, et al. ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-26. doi: 10.1111/jth.14810
40. Thygesen K, Alpert JS, Jaffe AS, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64. doi: 10.1016/j.jacc.2018.08.1038
41. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;e201585. doi: 10.1001/jama.2020.1585
42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
44. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. doi: 10.1001/jamacardio.2020.0950
45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
46. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;1-3. doi: 10.1007/s00134-020-05991-x
47. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190. doi: 10.1093/eurheartj/ehaa190
48. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164
49. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related Myocarditis in a 21-year-old Female Patient. Eur Heart J. 2020 Apr 13; ehaa288. doi: 10.1093/eurheartj/ehaa288
50. Irabien-Ortiz A. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020 Apr 10. doi: 10.1016/j.recesp.2020.04.001
51. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 Apr 20;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
52. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Apr 15;190:62. doi: 10.1016/j.thromres.2020.04.014
53. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013
54. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x
55. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;10.1001/jamacardio.2020.1096. doi: 10.1001/jamacardio.2020.1096
56. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X
57. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circulation Research. 2016;118:496-514. doi: 10.1161/CIRCRESAHA.115.306573
58. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. doi: 10.1056/NEJMoa2001191
59. WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
60. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-8. doi: 10.1111/jgh.15047
61. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238. PMID: 32077115.
62. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.0000000000000744
64. Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-5. doi: 10.1056/NEJMc2005073
65. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-34. doi: 10.1016/S1473-3099(20)30086-4
66. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-3.e3. doi: 10.1053/j.gastro.2020.02.055
67. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606
68. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-51. doi: 10.1111/apt.15731
69. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;10.1002/jmv.25757. doi: 10.1002/jmv.25757
70. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 May 12. doi: 10.1016/S2468-1253(20)30126-6
71. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. doi: 10.1016/S2468-1253(20)30057-1
72. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435
73. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055
74. de-Madaria E, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! Gastroenterology. 2020 Apr 21:S0016-5085(20)30561-8. doi: 10.1053/j.gastro.2020.04.044
75. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. PMID: 32387082.
76. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926
77. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-73. doi: 10.14309/ajg.0000000000000620
78. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7. doi: 10.3201/eid1009.040058
79. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
80. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0
81. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762
82. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
83. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-3. doi: 10.1126/science.abb2507
84. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
85. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. doi: 10.1097/JCMA.0000000000000319
86. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
87. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. doi: 10.1101/2020.02.03.931766
88. Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-81. doi: 10.1038/s41575-019-0125-y
89. Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018
90. Mukherjee R, Smith A, Sutton R. Covid-19-related pancreatic injury. Br J Surg. 2020 Apr 30. doi: 10.1002/bjs.11645. PMID: 32352160.
91. Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Apr 22:S1542-3565(20)30537-1.
92. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Apr 29;128:104386. doi: 10.1016/j.jcv.2020.104386
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-20. doi: 10.1097/JCMA.0000000000000270
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433
4. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
5. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577-82. doi: 10.7326/M20-0504. PMID: 32150748
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. PMID: 32091533.
7. Opening address by the Director-General at a COVID-19 press briefing on March 11, 2020. Published online at WHO.int. (In Russ.) https://www.who.int/ru/dg/speeches/detail/
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
8. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus
9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623
10. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8
11. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017. doi: 10.1001/jamacardio.2020.1017
12. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 17. doi: 10.1016/j.jacc.2020.04.031
13. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;10.1111/jce.14479. doi: 10.1111/jce.14479
14. Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727
15. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb Res. 2020 Apr 10;S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013
16. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;10.1161/CIRCRESAHA.120.317055. doi: 10.1161/CIRCRESAHA.120.317055
17. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally
in the Fight Against COVID-19. Circulation. 2020;10.1161/CIRCULATIONAHA.120.047008.
doi: 10.1161/CIRCULATIONAHA.120.047008
18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14850
19. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated With Coronavirus Disease 2019 Infection:
A Consensus Statement Before Guidelines. Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019
20. Tang N, Bai H, Chen X, et al. Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. doi: 10.1111/jth.14817
21. Marone EM, Rinaldi LF. Upsurge of Deep Venous Thrombosis in Patients Affected by COVID-19: Preliminary Data and Possible Explanations. J Vasc Surg Venous Lymphat Disord. 2020 Apr 17;S2213-333X(20)30214-6. doi: 10.1016/j.jvsv.2020.04.004
22. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024
23. Vulliamy P, Jacob S, Davenport RA. Acute Aorto-Iliac and Mesenteric Arterial Thromboses as Presenting Features of COVID-19. Br J Haematol. 2020 Apr 30. doi: 10.1111/bjh.16760
24. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant Acute Aortic Thrombosis and Pulmonary Embolism Complicating COVID-19 Pneumonia. Diagn Interv Imaging. 2020 Apr 16;101(5):321-2. doi: 10.1016/j.diii.2020.04.003
25. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 – A Swiss Consensus Statement by the Working Party Hemostasis. Swiss Med Wkly. 2020 Apr 11;150:w20247. doi: 10.4414/smw.2020.20247
26. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med. 2020 Apr 17: NEJMc2009020. doi: 10.1056/NEJMc2009020
27. Nikitskaya EA, Maryukhnich EV, Savvinova PP, et al. Human herpes viruses and atherosclerosis. Modern look. Creative cardiology. 2015;9(2):54-62 (In Russ.) doi: 10.15275/kreatkard.2015.02.05
28. Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae. 2016 Apr-Jun;8(2):102-7.
29. Nikitskaya E, Lebedeva A, Ivanova O, et al. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. J Am Heart Assoc. 2016 Aug 20;5(8):e003759. doi: 10.1161/JAHA.116.003759
30. Vorobyeva II, Ryzhkova EV, Vasilieva EYu, Spector AV. The effect of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome. Creative Cardiology. 2012;1:5-14 (In Russ.)
31. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;10.1164/rccm.202003-0543OC. doi: 10.1164/rccm.202003-0543OC
32. Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20.
33. Jing ZC, Zhu HD, Yan XW, et al.; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital, Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heat J. doi: 10.1093/eurheartj/ehaa258
34. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020 Apr 23. doi: 10.1016/S0140-6736(20)30912-0
35. Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Complicated With Fulminant Myocarditis: A Case Report and Insights. Infection. 2020 Apr 10. doi: 10.1007/s15010-020-01424-5
36. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Accessed May 10, 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
37. Courand P-Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous Coronary Artery Dissection in a Patient with COVID-19. JACC: Cardiovascular Interventions. 2020. doi: 10.1016/j.jcin.2020.04.006
38. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. doi: 10.1111/jth.14830
39. Thachil J, Tang N, Gando S, et al. ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-26. doi: 10.1111/jth.14810
40. Thygesen K, Alpert JS, Jaffe AS, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64. doi: 10.1016/j.jacc.2018.08.1038
41. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;e201585. doi: 10.1001/jama.2020.1585
42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
44. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. doi: 10.1001/jamacardio.2020.0950
45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
46. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;1-3. doi: 10.1007/s00134-020-05991-x
47. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190. doi: 10.1093/eurheartj/ehaa190
48. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164
49. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related Myocarditis in a 21-year-old Female Patient. Eur Heart J. 2020 Apr 13; ehaa288. doi: 10.1093/eurheartj/ehaa288
50. Irabien-Ortiz A. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020 Apr 10. doi: 10.1016/j.recesp.2020.04.001
51. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 Apr 20;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
52. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Apr 15;190:62. doi: 10.1016/j.thromres.2020.04.014
53. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013
54. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x
55. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;10.1001/jamacardio.2020.1096. doi: 10.1001/jamacardio.2020.1096
56. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X
57. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circulation Research. 2016;118:496-514. doi: 10.1161/CIRCRESAHA.115.306573
58. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. doi: 10.1056/NEJMoa2001191
59. WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
60. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-8. doi: 10.1111/jgh.15047
61. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238. PMID: 32077115.
62. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.0000000000000744
64. Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-5. doi: 10.1056/NEJMc2005073
65. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-34. doi: 10.1016/S1473-3099(20)30086-4
66. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-3.e3. doi: 10.1053/j.gastro.2020.02.055
67. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606
68. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-51. doi: 10.1111/apt.15731
69. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;10.1002/jmv.25757. doi: 10.1002/jmv.25757
70. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 May 12. doi: 10.1016/S2468-1253(20)30126-6
71. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. doi: 10.1016/S2468-1253(20)30057-1
72. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435
73. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055
74. de-Madaria E, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! Gastroenterology. 2020 Apr 21:S0016-5085(20)30561-8. doi: 10.1053/j.gastro.2020.04.044
75. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. PMID: 32387082.
76. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926
77. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-73. doi: 10.14309/ajg.0000000000000620
78. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7. doi: 10.3201/eid1009.040058
79. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
80. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0
81. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762
82. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
83. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-3. doi: 10.1126/science.abb2507
84. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
85. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. doi: 10.1097/JCMA.0000000000000319
86. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
87. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. doi: 10.1101/2020.02.03.931766
88. Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-81. doi: 10.1038/s41575-019-0125-y
89. Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018
90. Mukherjee R, Smith A, Sutton R. Covid-19-related pancreatic injury. Br J Surg. 2020 Apr 30. doi: 10.1002/bjs.11645. PMID: 32352160.
91. Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Apr 22:S1542-3565(20)30537-1.
92. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Apr 29;128:104386. doi: 10.1016/j.jcv.2020.104386
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-20. doi: 10.1097/JCMA.0000000000000270
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433
4. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
5. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577-82. doi: 10.7326/M20-0504. PMID: 32150748
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. PMID: 32091533.
7. Вступительное слово Генерального директора на пресс-брифинге по COVID-19 11 марта 2020 г. [Opening address by the Director-General at a COVID-19 press briefing on March 11, 2020. Published online at WHO.int. (In Russ.)]. https://www.who.int/ru/dg/speeches/detail/
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
8. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus
9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623
10. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8
11. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017. doi: 10.1001/jamacardio.2020.1017
12. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 17. doi: 10.1016/j.jacc.2020.04.031
13. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;10.1111/jce.14479. doi: 10.1111/jce.14479
14. Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727
15. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb Res. 2020 Apr 10;S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013
16. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;10.1161/CIRCRESAHA.120.317055. doi: 10.1161/CIRCRESAHA.120.317055
17. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation. 2020;10.1161/CIRCULATIONAHA.120.047008. doi: 10.1161/CIRCULATIONAHA.120.047008
18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14850
19. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated With Coronavirus Disease 2019 Infection:
A Consensus Statement Before Guidelines. Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019
20. Tang N, Bai H, Chen X, et al. Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. doi: 10.1111/jth.14817
21. Marone EM, Rinaldi LF. Upsurge of Deep Venous Thrombosis in Patients Affected by COVID-19: Preliminary Data and Possible Explanations. J Vasc Surg Venous Lymphat Disord. 2020 Apr 17;S2213-333X(20)30214-6. doi: 10.1016/j.jvsv.2020.04.004
22. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024
23. Vulliamy P, Jacob S, Davenport RA. Acute Aorto-Iliac and Mesenteric Arterial Thromboses as Presenting Features of COVID-19. Br J Haematol. 2020 Apr 30. doi: 10.1111/bjh.16760
24. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant Acute Aortic Thrombosis and Pulmonary Embolism Complicating COVID-19 Pneumonia. Diagn Interv Imaging. 2020 Apr 16;101(5):321-2. doi: 10.1016/j.diii.2020.04.003
25. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 – A Swiss Consensus Statement by the Working Party Hemostasis. Swiss Med Wkly. 2020 Apr 11;150:w20247. doi: 10.4414/smw.2020.20247
26. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med. 2020 Apr 17: NEJMc2009020. doi: 10.1056/NEJMc2009020
27. Никитская Е.А., Марюхнич Е.В., Саввинова П.П. и др. Вирусы герпеса человека и атеросклероз. Современный взгляд. Креативная кардиология. 2015;9(2):54-62 [Nikitskaya EA, Maryukhnich EV, Savvinova PP, et al. Human herpes viruses and atherosclerosis. Modern look. Creative cardiology. 2015;9(2):54-62 (In Russ.)]. doi: 10.15275/kreatkard.2015.02.05
28. Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae. 2016 Apr-Jun;8(2):102-7.
29. Nikitskaya E, Lebedeva A, Ivanova O, et al. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. J Am Heart Assoc. 2016 Aug 20;5(8):e003759. doi: 10.1161/JAHA.116.003759
30. Воробьева И.И., Рыжкова Е.В., Васильева Е.Ю., Шпектор А.В. Влияние системного воспаления на эффект антиагрегантной терапии у больных с острым коронарным синдромом. Креативная кардиология, 2012;1:5-14 [Vorobyeva II, Ryzhkova EV, Vasilieva EYu, Spector AV. The effect of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome. Creative Cardiology. 2012;1:5-14 (In Russ.)].
31. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;10.1164/rccm.202003-0543OC. doi: 10.1164/rccm.202003-0543OC
32. Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20.
33. Jing ZC, Zhu HD, Yan XW, et al.; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital, Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heat J. doi: 10.1093/eurheartj/ehaa258
34. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020 Apr 23. doi: 10.1016/S0140-6736(20)30912-0
35. Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Complicated With Fulminant Myocarditis: A Case Report and Insights. Infection. 2020 Apr 10. doi: 10.1007/s15010-020-01424-5
36. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Accessed May 10, 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
37. Courand P-Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous Coronary Artery Dissection in a Patient with COVID-19. JACC: Cardiovascular Interventions. 2020. doi: 10.1016/j.jcin.2020.04.006
38. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. doi: 10.1111/jth.14830
39. Thachil J, Tang N, Gando S, et al. ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-26. doi: 10.1111/jth.14810
40. Thygesen K, Alpert JS, Jaffe AS, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64. doi: 10.1016/j.jacc.2018.08.1038
41. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;e201585. doi: 10.1001/jama.2020.1585
42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
44. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. doi: 10.1001/jamacardio.2020.0950
45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
46. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;1-3. doi: 10.1007/s00134-020-05991-x
47. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190. doi: 10.1093/eurheartj/ehaa190
48. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164
49. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related Myocarditis in a 21-year-old Female Patient. Eur Heart J. 2020 Apr 13; ehaa288. doi: 10.1093/eurheartj/ehaa288
50. Irabien-Ortiz A. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020 Apr 10. doi: 10.1016/j.recesp.2020.04.001
51. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 Apr 20;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
52. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Apr 15;190:62. doi: 10.1016/j.thromres.2020.04.014
53. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013
54. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x
55. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;10.1001/jamacardio.2020.1096. doi: 10.1001/jamacardio.2020.1096
56. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X
57. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circulation Research. 2016;118:496-514. doi: 10.1161/CIRCRESAHA.115.306573
58. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. doi: 10.1056/NEJMoa2001191
59. WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
60. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-8. doi: 10.1111/jgh.15047
61. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238. PMID: 32077115.
62. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.0000000000000744
64. Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-5. doi: 10.1056/NEJMc2005073
65. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-34. doi: 10.1016/S1473-3099(20)30086-4
66. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-3.e3. doi: 10.1053/j.gastro.2020.02.055
67. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606
68. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-51. doi: 10.1111/apt.15731
69. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;10.1002/jmv.25757. doi: 10.1002/jmv.25757
70. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 May 12. doi: 10.1016/S2468-1253(20)30126-6
71. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. doi: 10.1016/S2468-1253(20)30057-1
72. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435
73. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055
74. de-Madaria E, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! Gastroenterology. 2020 Apr 21:S0016-5085(20)30561-8. doi: 10.1053/j.gastro.2020.04.044
75. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. PMID: 32387082.
76. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926
77. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-73. doi: 10.14309/ajg.0000000000000620
78. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7. doi: 10.3201/eid1009.040058
79. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
80. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0
81. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762
82. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
83. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-3. doi: 10.1126/science.abb2507
84. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
85. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. doi: 10.1097/JCMA.0000000000000319
86. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
87. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. doi: 10.1101/2020.02.03.931766
88. Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-81. doi: 10.1038/s41575-019-0125-y
89. Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018
90. Mukherjee R, Smith A, Sutton R. Covid-19-related pancreatic injury. Br J Surg. 2020 Apr 30. doi: 10.1002/bjs.11645. PMID: 32352160.
91. Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Apr 22:S1542-3565(20)30537-1.
92. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Apr 29;128:104386. doi: 10.1016/j.jcv.2020.104386
________________________________________________
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-20. doi: 10.1097/JCMA.0000000000000270
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433
4. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
5. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577-82. doi: 10.7326/M20-0504. PMID: 32150748
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. PMID: 32091533.
7. Opening address by the Director-General at a COVID-19 press briefing on March 11, 2020. Published online at WHO.int. (In Russ.) https://www.who.int/ru/dg/speeches/detail/
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
8. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus
9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623
10. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8
11. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017. doi: 10.1001/jamacardio.2020.1017
12. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 17. doi: 10.1016/j.jacc.2020.04.031
13. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;10.1111/jce.14479. doi: 10.1111/jce.14479
14. Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727
15. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb Res. 2020 Apr 10;S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013
16. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;10.1161/CIRCRESAHA.120.317055. doi: 10.1161/CIRCRESAHA.120.317055
17. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally
in the Fight Against COVID-19. Circulation. 2020;10.1161/CIRCULATIONAHA.120.047008.
doi: 10.1161/CIRCULATIONAHA.120.047008
18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14850
19. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated With Coronavirus Disease 2019 Infection:
A Consensus Statement Before Guidelines. Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019
20. Tang N, Bai H, Chen X, et al. Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. doi: 10.1111/jth.14817
21. Marone EM, Rinaldi LF. Upsurge of Deep Venous Thrombosis in Patients Affected by COVID-19: Preliminary Data and Possible Explanations. J Vasc Surg Venous Lymphat Disord. 2020 Apr 17;S2213-333X(20)30214-6. doi: 10.1016/j.jvsv.2020.04.004
22. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024
23. Vulliamy P, Jacob S, Davenport RA. Acute Aorto-Iliac and Mesenteric Arterial Thromboses as Presenting Features of COVID-19. Br J Haematol. 2020 Apr 30. doi: 10.1111/bjh.16760
24. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant Acute Aortic Thrombosis and Pulmonary Embolism Complicating COVID-19 Pneumonia. Diagn Interv Imaging. 2020 Apr 16;101(5):321-2. doi: 10.1016/j.diii.2020.04.003
25. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 – A Swiss Consensus Statement by the Working Party Hemostasis. Swiss Med Wkly. 2020 Apr 11;150:w20247. doi: 10.4414/smw.2020.20247
26. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med. 2020 Apr 17: NEJMc2009020. doi: 10.1056/NEJMc2009020
27. Nikitskaya EA, Maryukhnich EV, Savvinova PP, et al. Human herpes viruses and atherosclerosis. Modern look. Creative cardiology. 2015;9(2):54-62 (In Russ.) doi: 10.15275/kreatkard.2015.02.05
28. Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae. 2016 Apr-Jun;8(2):102-7.
29. Nikitskaya E, Lebedeva A, Ivanova O, et al. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. J Am Heart Assoc. 2016 Aug 20;5(8):e003759. doi: 10.1161/JAHA.116.003759
30. Vorobyeva II, Ryzhkova EV, Vasilieva EYu, Spector AV. The effect of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome. Creative Cardiology. 2012;1:5-14 (In Russ.)
31. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;10.1164/rccm.202003-0543OC. doi: 10.1164/rccm.202003-0543OC
32. Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20.
33. Jing ZC, Zhu HD, Yan XW, et al.; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital, Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heat J. doi: 10.1093/eurheartj/ehaa258
34. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020 Apr 23. doi: 10.1016/S0140-6736(20)30912-0
35. Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Complicated With Fulminant Myocarditis: A Case Report and Insights. Infection. 2020 Apr 10. doi: 10.1007/s15010-020-01424-5
36. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Accessed May 10, 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
37. Courand P-Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous Coronary Artery Dissection in a Patient with COVID-19. JACC: Cardiovascular Interventions. 2020. doi: 10.1016/j.jcin.2020.04.006
38. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. doi: 10.1111/jth.14830
39. Thachil J, Tang N, Gando S, et al. ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-26. doi: 10.1111/jth.14810
40. Thygesen K, Alpert JS, Jaffe AS, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64. doi: 10.1016/j.jacc.2018.08.1038
41. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;e201585. doi: 10.1001/jama.2020.1585
42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
44. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. doi: 10.1001/jamacardio.2020.0950
45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
46. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;1-3. doi: 10.1007/s00134-020-05991-x
47. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190. doi: 10.1093/eurheartj/ehaa190
48. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164
49. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related Myocarditis in a 21-year-old Female Patient. Eur Heart J. 2020 Apr 13; ehaa288. doi: 10.1093/eurheartj/ehaa288
50. Irabien-Ortiz A. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020 Apr 10. doi: 10.1016/j.recesp.2020.04.001
51. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 Apr 20;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
52. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Apr 15;190:62. doi: 10.1016/j.thromres.2020.04.014
53. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013
54. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x
55. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;10.1001/jamacardio.2020.1096. doi: 10.1001/jamacardio.2020.1096
56. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X
57. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circulation Research. 2016;118:496-514. doi: 10.1161/CIRCRESAHA.115.306573
58. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. doi: 10.1056/NEJMoa2001191
59. WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
60. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-8. doi: 10.1111/jgh.15047
61. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238. PMID: 32077115.
62. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.0000000000000744
64. Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-5. doi: 10.1056/NEJMc2005073
65. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-34. doi: 10.1016/S1473-3099(20)30086-4
66. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-3.e3. doi: 10.1053/j.gastro.2020.02.055
67. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606
68. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-51. doi: 10.1111/apt.15731
69. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;10.1002/jmv.25757. doi: 10.1002/jmv.25757
70. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 May 12. doi: 10.1016/S2468-1253(20)30126-6
71. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. doi: 10.1016/S2468-1253(20)30057-1
72. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435
73. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055
74. de-Madaria E, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! Gastroenterology. 2020 Apr 21:S0016-5085(20)30561-8. doi: 10.1053/j.gastro.2020.04.044
75. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. PMID: 32387082.
76. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926
77. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-73. doi: 10.14309/ajg.0000000000000620
78. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7. doi: 10.3201/eid1009.040058
79. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
80. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0
81. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762
82. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
83. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-3. doi: 10.1126/science.abb2507
84. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
85. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. doi: 10.1097/JCMA.0000000000000319
86. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
87. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. doi: 10.1101/2020.02.03.931766
88. Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-81. doi: 10.1038/s41575-019-0125-y
89. Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018
90. Mukherjee R, Smith A, Sutton R. Covid-19-related pancreatic injury. Br J Surg. 2020 Apr 30. doi: 10.1002/bjs.11645. PMID: 32352160.
91. Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Apr 22:S1542-3565(20)30537-1.
92. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Apr 29;128:104386. doi: 10.1016/j.jcv.2020.104386
Авторы
И.В. Маев, А.В. Шпектор, Е.Ю. Васильева, В.Н. Манчуров, Д.Н. Андреев
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России,
Москва, Россия
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России,
Москва, Россия
________________________________________________
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.